Skip to main content
Erschienen in: Journal of Interventional Cardiac Electrophysiology 3/2024

02.08.2023

Thirty-day readmission after catheter ablation for ventricular tachycardia: associated factors and outcomes

verfasst von: Min Choon Tan, Qi Xuan Ang, Yong Hao Yeo, Abhishek Deshmukh, Luis R. Scott, Ayman A. Hussein, Jakub Sroubek, Pasquale Santangeli, Oussama M. Wazni, Justin Z. Lee

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with ventricular tachycardia (VT) who require VT ablation are at high risk for readmission. This study aimed to identify the causes and outcomes of 30-day readmission after VT ablation and to analyze the predictors of recurrent VT that required rehospitalization.

Methods

Using the Nationwide Readmission Database, our study included patients aged ≥ 18 years who underwent VT catheter ablation between 2017 and 2020. Based on the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), we identified the causes of 30-day readmission by organ systems and analyzed their outcomes. Additional analysis was performed to determine the independent predictors of 30-day readmission for recurrent VT.

Results

Of the 4228 patients who underwent VT ablation, 14.2% were readmitted within 30 days of the procedure. The most common cause of readmission was cardiac events (73.6%). Among the cardiac-related readmissions, recurrent VT (47.7%) and congestive heart failure (CHF) (12.9%) were the most common etiologies. Among the readmissions, patients readmitted for CHF had the highest rate of readmission mortality (9.2%). Of the patients readmitted within 30 days of the procedure, 278 patients (6.8%) were readmitted for recurrent VT. Via multivariable analysis, CHF (OR: 1.97; 95% CI: 1.12–3.47; P = 0.02) and non-elective index admissions (OR: 1.63; 95% CI: 1.04–2.55; P = 0.03) were identified as the independent predictors predictive of 30-day readmissions for recurrent VT.

Conclusions

Recurrent VT was the most common cause of readmission after the VT ablation procedure, and CHF and non-elective index admissions were the significant predictors of these early readmissions. Readmission due to CHF had the highest mortality rate during readmission.
Literatur
1.
Zurück zum Zitat Al-Khatib SM, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):1677–749.CrossRefPubMed Al-Khatib SM, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):1677–749.CrossRefPubMed
2.
Zurück zum Zitat Sapp JL, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111–21.CrossRefPubMed Sapp JL, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111–21.CrossRefPubMed
3.
Zurück zum Zitat Tung R, et al. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial. Circulation. 2022;145(25):1839–49.CrossRefPubMed Tung R, et al. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial. Circulation. 2022;145(25):1839–49.CrossRefPubMed
4.
Zurück zum Zitat Cheung JW, et al. Outcomes, costs, and 30-day readmissions after catheter ablation of myocardial infarct-associated ventricular tachycardia in the real world: Nationwide Readmissions Database 2010 to 2015. Circ Arrhythm Electrophysiol. 2018;11(11):e006754.CrossRefPubMed Cheung JW, et al. Outcomes, costs, and 30-day readmissions after catheter ablation of myocardial infarct-associated ventricular tachycardia in the real world: Nationwide Readmissions Database 2010 to 2015. Circ Arrhythm Electrophysiol. 2018;11(11):e006754.CrossRefPubMed
5.
Zurück zum Zitat Briceno DF, et al. Catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy: a propensity score-matched analysis of in-hospital outcomes in the United States. J Cardiovasc Electrophysiol. 2018;29(5):771–9.CrossRefPubMed Briceno DF, et al. Catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy: a propensity score-matched analysis of in-hospital outcomes in the United States. J Cardiovasc Electrophysiol. 2018;29(5):771–9.CrossRefPubMed
9.
Zurück zum Zitat Tung R, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12(9):1997–2007.CrossRefPubMedPubMedCentral Tung R, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12(9):1997–2007.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Nazarian S, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005;112(18):2821–5.CrossRefPubMedPubMedCentral Nazarian S, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005;112(18):2821–5.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Santangeli P, et al. Management of ventricular arrhythmias in patients with advanced heart failure. J Am Coll Cardiol. 2017;69(14):1842–60.CrossRefPubMed Santangeli P, et al. Management of ventricular arrhythmias in patients with advanced heart failure. J Am Coll Cardiol. 2017;69(14):1842–60.CrossRefPubMed
12.
Zurück zum Zitat Yokokawa M, et al. The characteristics and distribution of the scar tissue predict ventricular tachycardia in patients with advanced heart failure. Pacing Clin Electrophysiol. 2009;32(3):314–22.CrossRefPubMed Yokokawa M, et al. The characteristics and distribution of the scar tissue predict ventricular tachycardia in patients with advanced heart failure. Pacing Clin Electrophysiol. 2009;32(3):314–22.CrossRefPubMed
13.
Zurück zum Zitat Becher RD, et al. A critical assessment of outcomes in emergency versus nonemergency general surgery using the American College of Surgeons National Surgical Quality Improvement Program database. Am Surg. 2011;77(7):951–9.CrossRefPubMed Becher RD, et al. A critical assessment of outcomes in emergency versus nonemergency general surgery using the American College of Surgeons National Surgical Quality Improvement Program database. Am Surg. 2011;77(7):951–9.CrossRefPubMed
14.
Zurück zum Zitat Willems S, et al. Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable defibrillator (BERLIN VT): a multicenter randomized trial. Circulation. 2020;141(13):1057–67.CrossRefPubMed Willems S, et al. Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable defibrillator (BERLIN VT): a multicenter randomized trial. Circulation. 2020;141(13):1057–67.CrossRefPubMed
15.
Zurück zum Zitat Lee JZ, et al. Causes of early mortality after ventricular tachycardia ablation in patients with reduced ejection fraction. JACC Clin Electrophysiol. 2022 Lee JZ, et al. Causes of early mortality after ventricular tachycardia ablation in patients with reduced ejection fraction. JACC Clin Electrophysiol.  2022
Metadaten
Titel
Thirty-day readmission after catheter ablation for ventricular tachycardia: associated factors and outcomes
verfasst von
Min Choon Tan
Qi Xuan Ang
Yong Hao Yeo
Abhishek Deshmukh
Luis R. Scott
Ayman A. Hussein
Jakub Sroubek
Pasquale Santangeli
Oussama M. Wazni
Justin Z. Lee
Publikationsdatum
02.08.2023
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 3/2024
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-023-01614-9

Weitere Artikel der Ausgabe 3/2024

Journal of Interventional Cardiac Electrophysiology 3/2024 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.